wwikiqo
About

NH130

Pharmaceutical compound

NH130 is a highly selective serotonin 5-HT2A receptor inverse agonist which is under development for the treatment of Parkinson's disease psychosis. It is taken orally. The drug's time to peak levels is 3.0 to 4.5 hours and its elimination half-life is 13.7 to 18.2 hours. NH130 is under development by Jiangsu Nhwa Pharmaceutical in China. As of November 2025, it is in phase 2 clinical trials.

NH130

NH130
Clinical data
Other namesNH-130
Routes of
administration		Oral[1][2]
Drug classSerotonin 5-HT2A receptor antagonist; Antipsychotic
Pharmacokinetic data
Onset of action3.0–4.5 hours (TmaxTooltip time to peak levels
Elimination half-life13.7–18.2 hours[2]

NH130 is a highly selective serotonin 5-HT2A receptor inverse agonist which is under development for the treatment of Parkinson's disease psychosis.[3][1][4][2] It is taken orally.[1][2] The drug's time to peak levels is 3.0 to 4.5 hours and its elimination half-life is 13.7 to 18.2 hours.[2] NH130 is under development by Jiangsu Nhwa Pharmaceutical in China.[3][1][2] As of November 2025, it is in phase 2 clinical trials.[3]

See also

References

  1. 1 2 3 4 "NH-130 Drug Profile". Ozmosi. Retrieved 18 January 2026.
  2. 1 2 3 4 5 6 Zhang K, Zhao S, Du J, Zhang L (2024). "Phase I clinical trial of NH130 and the prediction of its pharmacokinetics using physiologically based pharmacokinetic modeling". Frontiers in Pharmacology. 15 1474868. doi:10.3389/fphar.2024.1474868. PMC 11424876. PMID 39329116. Following the success of pimavanserin, the search for new molecules with enhanced efficacy and an improved safety profile for treating PDP began. In Phase 1 clinical trial (CTR20230409), healthy volunteers received the compound NH130, a highly selective inverse agonist of the 5-HT2AR designed to mimic pimavanserin. The results confirmed NH130's favourable safety and tolerability. Based on these findings, further optimization of the compound and Phase 2 studies in patients with PDP are planned (K. Zhang et al., 2024).
  3. 1 2 3 "Delving into the Latest Updates on NH-130 with Synapse". Synapse. 21 November 2025. Retrieved 18 January 2026.
  4. ↑ Fryc M, Kluzik D, Czopek A, Jończyk J, Zagórska A (November 2025). "Serotonin 2A (5-HT2A) receptor as evolving biological target: function, structure, ligands and role in the therapy of neuropsychiatric diseases". Neuropharmacology. 279 110622. doi:10.1016/j.neuropharm.2025.110622. PMID 40752586.